Obesity drug sales help Novo Nordisk beat expectations
Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations. The company on Wednesday reported that net sales increased by 26 per cent year on year in 2024 to DKr290bn ($40bn),
Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...
An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...
Comprehensive study exposes critical health risks of obesity, including diabetes, heart disease, and cancer, while offering ...
Obesity affects both physical and mental health, leading to body-image issues and emotional eating. Dr. Nand Kumar of AIIMS ...
Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online ...
The economic burden of obesity is also significant. In the Finger Lakes, excess medical spending due to obesity is estimated ...
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...
The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...
Major heart health risk factors like obesity, diabetes and high blood pressure remain on the rise in the United States, ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
A positive response to treatment for pediatric obesity has enduring health benefits into young adulthood, according to a study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback